We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pfizer's Rare Disease Candidate Meets Endpoint in Phase III
Read MoreHide Full Article
Pfizer Inc. (PFE - Free Report) announced that a phase III study evaluating its pipeline candidate tafamidis for the treatment of transthyretin cardiomyopathy (TTR-CM) met its primary endpoint.
Top line data from the ATTR-ACT study showed that treatment with tafamidis led to a statistically significant reduction in the combination of all-cause mortality and frequency of cardiovascular-related hospitalizations – the primary endpoint - compared with the placebo at 30 months. The safety data also demonstrated that tafamidis was generally well tolerated by patients.
After Pfizer revealed strong late-stage results from the tafamidis study, shares of Alnylam Pharmaceuticals (ALNY - Free Report) and Ionis Pharmaceuticals (IONS - Free Report) declined more than 8% and 4%, respectively, on Friday. Both these biotechs have made competing drugs to tafamidis.
TTR-CM is a rare disease associated with progressive heart failure and is universally fatal. Presently, no treatment is approved to treat this fatal disease. According to Pfizer’s press release, less than 1% of people with the disease are diagnosed with life expectancy averaging three to five years from diagnosis.
There are two types of TTR-CM, a hereditary form and a wild-type form of the disease, which is not hereditary. The ATTR-ACT study included both types of patients. However, Alnylam and Ionis have developed their candidates, patisiran and inotersen, respectively, for hereditary TTR amyloidosis, or hATTR. Both patisiran and inotersen are under review in the EU and United States and could be launched this year.
Tafamidis has been granted fast track status by FDA for TTR-CM. Meanwhile, tafamidis also enjoys orphan drug designation for TTR-CM in both the EU and United States.
Tafamidis is already approved for the treatment of transthyretin familial amyloid polyneuropathy (TTR-FAP) in 40 countries except United States. In the United States, Pfizer received a complete response letter (CRL) from the FDA on for TTR-FAP in 2012.
Shares of Pfizer have declined 1.1% so far this year, comparing favorably with a 2.7% decrease for the industry.
Another top-ranked large-cap pharma stock is H. Lundbeck with the same Zacks Rank as Pfizer.
Shares of H. Lundbeck have returned 12.9% this year so far. Estimates for 2018 increased 8.5% over the past 60 days.
Can Hackers Put Money INTO Your Portfolio?
Earlier this month, credit bureau Equifax announced a massive data breach affecting 2 out of every 3 Americans. The cybersecurity industry is expanding quickly in response to this and similar events. But some stocks are better investments than others.
Zacks has just released Cybersecurity! An Investor’s Guide to help Zacks.com readers make the most of the $170 billion per year investment opportunity created by hackers and other threats. It reveals 4 stocks worth looking into right away.
Image: Bigstock
Pfizer's Rare Disease Candidate Meets Endpoint in Phase III
Pfizer Inc. (PFE - Free Report) announced that a phase III study evaluating its pipeline candidate tafamidis for the treatment of transthyretin cardiomyopathy (TTR-CM) met its primary endpoint.
Top line data from the ATTR-ACT study showed that treatment with tafamidis led to a statistically significant reduction in the combination of all-cause mortality and frequency of cardiovascular-related hospitalizations – the primary endpoint - compared with the placebo at 30 months. The safety data also demonstrated that tafamidis was generally well tolerated by patients.
After Pfizer revealed strong late-stage results from the tafamidis study, shares of Alnylam Pharmaceuticals (ALNY - Free Report) and Ionis Pharmaceuticals (IONS - Free Report) declined more than 8% and 4%, respectively, on Friday. Both these biotechs have made competing drugs to tafamidis.
TTR-CM is a rare disease associated with progressive heart failure and is universally fatal. Presently, no treatment is approved to treat this fatal disease. According to Pfizer’s press release, less than 1% of people with the disease are diagnosed with life expectancy averaging three to five years from diagnosis.
There are two types of TTR-CM, a hereditary form and a wild-type form of the disease, which is not hereditary. The ATTR-ACT study included both types of patients. However, Alnylam and Ionis have developed their candidates, patisiran and inotersen, respectively, for hereditary TTR amyloidosis, or hATTR. Both patisiran and inotersen are under review in the EU and United States and could be launched this year.
Tafamidis has been granted fast track status by FDA for TTR-CM. Meanwhile, tafamidis also enjoys orphan drug designation for TTR-CM in both the EU and United States.
Tafamidis is already approved for the treatment of transthyretin familial amyloid polyneuropathy (TTR-FAP) in 40 countries except United States. In the United States, Pfizer received a complete response letter (CRL) from the FDA on for TTR-FAP in 2012.
Shares of Pfizer have declined 1.1% so far this year, comparing favorably with a 2.7% decrease for the industry.
Zacks Rank & Key Pick
Pfizer carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Another top-ranked large-cap pharma stock is H. Lundbeck with the same Zacks Rank as Pfizer.
Shares of H. Lundbeck have returned 12.9% this year so far. Estimates for 2018 increased 8.5% over the past 60 days.
Can Hackers Put Money INTO Your Portfolio?
Earlier this month, credit bureau Equifax announced a massive data breach affecting 2 out of every 3 Americans. The cybersecurity industry is expanding quickly in response to this and similar events. But some stocks are better investments than others.
Zacks has just released Cybersecurity! An Investor’s Guide to help Zacks.com readers make the most of the $170 billion per year investment opportunity created by hackers and other threats. It reveals 4 stocks worth looking into right away.
Download the new report now>>